Surgical Science Sweden AB (0AAU), the Gothenburg-headquartered medical simulation specialist listed on Nasdaq First North Growth Market, published its interim report for the nine months ended 30 September 2026 on 12 November 2026. Third-quarter net sales edged down 1 percent year-on-year to SEK 260.2 million, yet net profit surged to SEK 34.1 million from SEK 20.4 million in the same period a year earlier. For the first nine months of 2026, net sales grew 4 percent to SEK 750.2 million, with earnings per share doubling to SEK 1.44 from SEK 0.66, figures that investors in the medical technology simulation sector are likely to scrutinise closely.

Key Points

  • Surgical Science Sweden AB (0AAU), traded on Nasdaq First North Growth Market, Stockholm
  • Q3 2026 net profit rose to SEK 34.1 million from SEK 20.4 million despite a 1 percent decline in quarterly net sales to SEK 260.2 million
  • Nine-month net sales reached SEK 750.2 million; operating cash flow improved sharply to SEK 123.1 million from SEK 6.9 million year-on-year
  • Investors will be watching whether licence revenue, which accounted for 30 percent of nine-month net sales, continues to expand as a proportion of the revenue mix

Surgical Science Q3 2026 Revenue Dips 1 Percent but Gross Margin Widens to 68 Percent

In the third quarter ending 30 September 2026, Surgical Science recorded net sales of SEK 260.2 million, compared with SEK 263.6 million in the equivalent quarter of the prior year — a 1 percent decline both in reported terms and in local currencies. Despite the modest revenue contraction, the gross margin expanded to 68 percent from 65 percent, while operating profit improved to SEK 32.0 million from SEK 27.2 million. The quarter's earnings per share reached SEK 0.67, up from SEK 0.40 previously, reflecting tighter cost management and a more favourable revenue mix within the period.

Licence Revenue Growth and Cash Generation Drive Nine-Month Performance for Surgical Science

Across the first nine months of 2026, licence revenue totalled SEK 228.4 million, representing 30 percent of net sales compared with 29 percent and SEK 208.3 million in the same period a year earlier. The nine-month gross margin held at 68 percent versus 66 percent previously, and operating profit reached SEK 87.5 million, sharply ahead of SEK 28.7 million year-on-year. Operating cash flow transformed to SEK 123.1 million from just SEK 6.9 million, and cash and cash equivalents stood at SEK 674.9 million as at 30 September 2026, the announcement states.

Global VR Surgical Simulation Operations Underpin Surgical Science's Revenue Model

Surgical Science describes itself as a global leader in evidence-based medical simulation, providing virtual reality simulators and customised training solutions that enable surgeons and healthcare professionals to practise skills outside the operating room. The company, which employs approximately 320 people, operates from offices in Gothenburg, Tel Aviv, Stockholm, Cleveland, Cardiff, Hong Kong, and Shenzhen. It also partners with medical technology and robotics companies to integrate simulation technology directly into their devices, creating a dual revenue stream of product sales and recurring licence fees that the latest results suggest is becoming increasingly significant.

Currency Exposure and Single-Quarter Revenue Softness Among Risks Investors May Monitor

The announcement highlights that nine-month local-currency revenue growth of 5 percent slightly exceeded the reported 4 percent figure, indicating that currency translation has a discernible impact on Surgical Science's results given its broad international footprint. The 1 percent quarterly revenue decline, even when measured in local currencies, may invite scrutiny around near-term demand trends for simulation hardware and services. The company did not disclose forward guidance in the announcement, leaving investors to assess the trajectory of licence revenue expansion and operating leverage as the final quarter of 2026 approaches.